Akebia Therapeutics Inc. (NASDAQ: AKBA) stock closed at 0.3986 per share at the end of the most recent trading day (a -4.11% change compared to the prior day closing price) with a volume of 3.16M shares and market capitalization of 73.28M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 360 people. Akebia Therapeutics Inc. CEO is John P. Butler.

The one-year performance of Akebia Therapeutics Inc. stock is -83.82%, while year-to-date (YTD) performance is -82.36%. AKBA stock has a five-year performance of -97.21%. Its 52-week range is between 0.3 and 3.35, which gives AKBA stock a 52-week price range ratio of 3.23%

Akebia Therapeutics Inc. currently has a PE ratio of -0.30, a price-to-book (PB) ratio of 2.96, a price-to-sale (PS) ratio of 0.43, a price to cashflow ratio of 10.50, a PEG ratio of 2.32, a ROA of -48.84%, a ROC of -110.18% and a ROE of -241.73%. The company’s profit margin is -83.74%, its EBITDA margin is -98.70%, and its revenue ttm is $170.06 Million , which makes it $0.93 revenue per share.

Of the last four earnings reports from Akebia Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.29 for the next earnings report. Akebia Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Akebia Therapeutics Inc. is Hold (3), with a target price of $1.75, which is +339.04% compared to the current price. The earnings rating for Akebia Therapeutics Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Akebia Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Akebia Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 22.00, ATR14 : 0.04, CCI20 : -15.37, Chaikin Money Flow : -0.07, MACD : 0.00, Money Flow Index : 41.57, ROC : -1.58, RSI : 39.32, STOCH (14,3) : 52.18, STOCH RSI : 0.60, UO : 54.30, Williams %R : -47.82), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Akebia Therapeutics Inc. in the last 12-months were: David A. Spellman (Sold 8 203 shares of value $17 689 ), Dell Faulkingham (Sold 13 184 shares of value $28 515 ), John P. Butler (Sold 79 026 shares of value $171 143 ), Michel Dahan (Sold 14 660 shares of value $31 718 ), Nicole R. Hadas (Sold 21 062 shares of value $45 615 ), Steven C. Gilman (Sold 4 567 shares of value $1 653 ), Steven Keith Burke (Sold 16 098 shares of value $35 513 ), Violetta Cotreau (Sold 9 779 shares of value $21 838 )